AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32639634
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (10 mg/kg daily)
Trial: 32639634
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (5 mg/kg daily)
Trial: 32981056
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 5 μg/kg/min (K1 group)
Trial: 32981056
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 10 μg/kg/min (K2 group)
Trial: 32981056
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 20 μg/kg/min (K3 group)
Trial: 36066501
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTA) injections
Trial: 35007748
Drug: Crimson duvet
RxNorm normalized name: crimson bottlebrush pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crimson duvet procedure (CDP) with microfracture treatment of the footprint
Trial: 35090154
Drug: Suppressive valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive valacyclovir treatment for 1 year
Trial: 33749386
Drug: G-computation method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-computation method
Trial: 33753652
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 1 week
Trial: 33753652
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 2 weeks
Trial: 33753652
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 3 weeks
Trial: 36330051
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene Blue (MB) injection
Trial: 34534517
Drug: Voluntary daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary daily lateral flow device (LFD) testing for 7 days with LFD-negative contacts remaining at school
Trial: 32270638
Drug: Simple manipulative
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple manipulative therapy
Trial: 36148467
Drug: Avidekel oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avidekel oil (30% cannabidiol and 1% tetrahydrocannabinol: 295 mg and 12.5 mg per ml)
Trial: 34243808
Drug: Self-administered mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered mirror therapy (MT) education in addition to regular rehabilitation interventions for 4 weeks
Trial: 35380419
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate citrate (FPC) administered as a single intravenous dose of 6.5 mg to healthy subjects.
Trial: 35380419
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate citrate (FPC) administered at two sequential hemodialysis treatments: HD dose 1 (27.2 mg at 95 μg/L for 4 h) and HD dose 2 (6.5 mg via pre-dialyzer blood circuit).
Trial: 35380419
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of PK parameters between HD dose 1 and HD dose 2.
Trial: 32560739
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of active ZHWFG three times daily
Trial: 32560739
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of active ZHWFG plus 5 g of ZHWFG‐matched placebo three times daily
Trial: 32560739
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of ZHWFG‐matched placebo three times daily
Trial: 33876784
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with 0, 50, 100 or 150 mg of epidural ropivacaine
Trial: 33876784
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at concentrations up to 6 μg ml-1
Trial: 33876784
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of epidural anaesthesia and intravenous propofol
Trial: 33586626
Drug: Initial Aqualizer™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial Aqualizer™ therapy (Group 1)
Trial: 33586626
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial therapy (Group 2)
Trial: 32448382
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily Biphasic Human Insulin 30 (BHI 30)
Trial: 32448382
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily Biphasic Human Insulin 30 (BHI 30)
Trial: 35430718
Drug: Aerosolized capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized capsaicin (AC), 1-10 drops of liquid cayenne extract (1.5-2% capsaicin) in 100 mL carbonated water.
Trial: 33275318
Drug: Imeglimin 500
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 500 mg
Trial: 33275318
Drug: Imeglimin 1500
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 1500 mg
Trial: 32400903
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) adapted for SE-AN
Trial: 35723225
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (metformin/pioglitazone/exenatide)
Trial: 33571026
Drug: Ginkgolide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgolide plus aspirin
Trial: 32988524
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 3 ppm Cx and 34.5 μg 25-OH-D3
Trial: 32988524
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 6 ppm Cx and 69 μg 25-OH-D3
Trial: 32988524
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 9 ppm Cx and 103.5 μg 25-OH-D3
Trial: 32988524
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 12 ppm Cx and 138 μg 25-OH-D3
Trial: 39466236
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily for 8 weeks
Trial: 35830338
Drug: Low-Intensity Shock
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Shock Wave Therapy (LiST)
Trial: 32085823
Drug: ART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART plus vorinostat and T-cell inducing vaccines (ART + V + V)
Trial: 32475440
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g C. lanatus essential oil/kg feed (1gCL)
Trial: 32475440
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g C. lanatus essential oil/kg feed (2gCL)
Trial: 35322637
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (basic treatment, Qiming granules, individualized Chinese herbal medicines)
Trial: 35322637
Drug: Stationary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stationary treatment (basic treatment and Qiming granules)
Trial: 32880495
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg twice a day) in combination with docetaxel
Trial: 32880495
Drug: Selumetinib (monotherapy)
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib (monotherapy)
Trial: 32880495
Drug: Selumetinib (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (in combination with docetaxel)
Trial: 33610365
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (combination of 4 drugs: ACE inhibitor or ARB, beta-blocker, statin, and 1 antiplatelet drug)
Trial: 33610365
Drug: Coronary artery
RxNorm normalized name: Drug-coated coronary artery stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary artery bypass grafting with medical therapy
Trial: 34432302
Drug: PAS-calcium formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAS-calcium formulation (PAS-Ca)
Trial: 33256420
Drug: Endoscopic tattooing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic tattooing with two injection points and 1 ml of labeling volume
Trial: 33256420
Drug: Endoscopic tattooing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic tattooing with three injection points and 1.5 ml of labeling volume
Trial: 33256420
Drug: Endoscopic tattooing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic tattooing with two injection points and 1.5 ml of labeling volume
Trial: 33256420
Drug: Endoscopic tattooing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic tattooing with three injection points and 1 ml of labeling volume
Trial: 32230754
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVOO), 50 mL daily for 3 weeks
Trial: 32230754
Drug: Refined olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined olive oil (ROO), 50 mL daily for 3 weeks
Trial: 36227782
Drug: Linaclotide 290
RxNorm normalized name: LINACLOTIDE 290MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaclotide 290 μg
Trial: 33851518
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg daily for a week
Trial: 33851518
Drug: Rifampicin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin treatment
Trial: 32333325
Drug: Selonsertib (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib (1, 3, 10, 30, or 100 mg)
Trial: 32333325
Drug: Selonsertib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib (various doses)
Trial: 32195961
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to the soft palate and tongue base, 8 seconds per point, twice a week for 2 months using Therapy Plus NS 13678 Laser.
Trial: 34370681
Drug: Topical treatments
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatments for oral mucositis as per Mucositis Guidelines
Trial: 35717342
Drug: NaPB 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaPB 4.8 g/m²/day
Trial: 33336219
Drug: Lemborexant 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 2.5 mg
Trial: 33336219
Drug: Lemborexant 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 15 mg
Trial: 36412916
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (three 30-minute sessions weekly during chemotherapy)
Trial: 36412916
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard breast cancer treatment without yoga)
Trial: 33045913
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol + micronised progesterone
Trial: 33045913
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol + medroxyprogesterone acetate
Trial: 32629446
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by cetuximab and RT (IBRT)
Trial: 32629446
Drug: Cisplatin concurrent
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin concurrent with RT (CRT)
Trial: 34077270
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg IV every 3 weeks for 17 cycles
Trial: 34077270
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus trastuzumab (TH) 80 mg/m2 IV with H once every week for 12 weeks followed by H for 39 weeks
Trial: 33581997
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment with water resistance therapy (WRT) plus vocal hygiene program (n = 12)
Trial: 33649930
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg doxorubicin (group A)
Trial: 33649930
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxorubicin (group B)
Trial: 32106110
Drug: Blocking GDF15
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking GDF15 with a neutralizing antibody
Trial: 35256489
Drug: Low-flow anesthesia
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow anesthesia (1 L.min‐1 after initial 6 L.min‐1 for 10 minutes)
Trial: 35256489
Drug: Mid-flow anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-flow anesthesia (2 L.min‐1)
Trial: 35256489
Drug: High-flow anesthesia
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow anesthesia (4 L.min‐1)
Trial: 33594772
Drug: GI-6301 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI-6301 vaccine (80 × 10^7 yeast cells)
Trial: 32268771
Drug: Group D1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D1: perineural administration of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Trial: 32268771
Drug: Group D2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D2: intravenous infusion of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Trial: 34617341
Drug: Implant-level (IL)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-level (IL) connection
Trial: 33544240
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg once daily for 40 weeks
Trial: 35710320
Drug: Clemastine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine (active treatment), n=53, geometric mean=6.33 pg/mL
Trial: 35710320
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, n=73, geometric mean=7.00 pg/mL
Trial: 35710320
Drug: Clemastine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine (active treatment)
Trial: 33249609
Drug: Full prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full prophylaxis (palivizumab doses for each month of RSV exposure)
Trial: 33251697
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (IGlu)
Trial: 33461782
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg
Trial: 35764956
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy plus PD‐1 antibody with preoperative chemoradiation (Arm A)
Trial: 35764956
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy plus PD‐1 antibody without preoperative chemoradiation (Arm B)
Trial: 34525285
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide typhoid conjugate vaccine (Vi-TCV)
Trial: 38281499
Drug: Meningococcal capsular
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal capsular group A conjugate (MenA) vaccine
Trial: 32926834
Drug: Co-administered Na-GST-1
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered Na-GST-1 and Na-APR-1 (M74) vaccines (30 μg or 100 μg of each), adjuvanted with Alhydrogel and glucopyranosyl lipid A, administered intramuscularly on days 0, 28, and 180.
Trial: 32926834
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received hepatitis B vaccine plus saline, administered intramuscularly on days 0, 28, and 180.
Trial: 33264544
Drug: Chemotherapy (5-fluorouracil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab every 2 weeks)
Trial: 33143212
Drug: Phaseolus Vulgaris
RxNorm normalized name: PHASEOLUS VULGARIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phaseolus Vulgaris (PV) consumption, 250 g as an extract thrice weekly for 6 weeks
Trial: 32698634
Drug: Triphala (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphala (1 g standardized as 91.82 ± 0.5 mg gallic acid, administered BID)
Trial: 32698634
Drug: Placebo (wheat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (wheat flour, administered BID)
Trial: 33900931
Drug: cCBT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cCBT + treatment as usual (TAU)
Trial: 33845941
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural steroid injection
Trial: 33115285
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg/2 weeks after 160 mg initial dose)
Trial: 33115285
Drug: Secukinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks)
Trial: 35929973
Drug: Investigational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational treatment arm
Trial: 32439266
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of GAA for 4 weeks
Trial: 34289222
Drug: Mebeverine 200
RxNorm normalized name: mebeverine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 200 mg once a day for 3 months
Trial: 35831045
Drug: Oral pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pravastatin
Trial: 32650673
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for vulvodynia
Trial: 34192922
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional oral regime for 24 hours postoperatively
Trial: 34192922
Drug: Only intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only intraoperative dose of TXA
Trial: 35317789
Drug: Automated Treatment
RxNorm normalized name: Automated peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated Treatment (AT), n=250, consisting of a fully-automated smartphone-based intervention with 10 weeks of nicotine replacement therapy (NRT) including transdermal patches and lozenges.